3.12
price down icon2.50%   -0.08
 
loading
Schlusskurs vom Vortag:
$3.20
Offen:
$3.15
24-Stunden-Volumen:
282.79K
Relative Volume:
0.43
Marktkapitalisierung:
$736.26M
Einnahmen:
$596.48M
Nettoeinkommen (Verlust:
$123.72M
KGV:
5.6893
EPS:
0.5484
Netto-Cashflow:
$106.59M
1W Leistung:
+9.09%
1M Leistung:
+1.63%
6M Leistung:
+10.64%
1J Leistung:
+21.40%
1-Tages-Spanne:
Value
$3.07
$3.16
1-Wochen-Bereich:
Value
$2.91
$3.29
52-Wochen-Spanne:
Value
$2.215
$5.28

Curevac N V Stock (CVAC) Company Profile

Name
Firmenname
Curevac N V
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
1,088
Name
Twitter
Name
Nächster Verdiensttermin
2025-04-10
Name
Neueste SEC-Einreichungen
Name
CVAC's Discussions on Twitter

Vergleichen Sie CVAC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CVAC
Curevac N V
3.12 736.26M 596.48M 123.72M 106.59M 0.5484
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.10 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.16 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
596.20 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.56 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
230.98 26.16B 3.81B -644.79M -669.77M -6.24

Curevac N V Stock (CVAC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-04-25 Herabstufung Leerink Partners Outperform → Market Perform
2023-06-08 Eingeleitet SVB Securities Outperform
2023-01-19 Hochstufung UBS Neutral → Buy
2023-01-09 Hochstufung Jefferies Hold → Buy
2022-01-21 Herabstufung BofA Securities Neutral → Underperform
2022-01-18 Eingeleitet JMP Securities Mkt Outperform
2021-10-22 Eingeleitet Deutsche Bank Hold
2021-06-17 Herabstufung BofA Securities Buy → Neutral
2021-04-26 Fortgesetzt Credit Suisse Underperform
2021-04-26 Eingeleitet Guggenheim Neutral
2020-12-10 Herabstufung Credit Suisse Neutral → Underperform
2020-09-08 Eingeleitet BofA Securities Buy
2020-09-08 Eingeleitet Credit Suisse Neutral
2020-09-08 Eingeleitet Jefferies Hold
Alle ansehen

Curevac N V Aktie (CVAC) Neueste Nachrichten

pulisher
Apr 14, 2025

CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance

Apr 14, 2025
pulisher
Apr 13, 2025

CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy? - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript - Insider Monkey

Apr 12, 2025
pulisher
Apr 11, 2025

CureVac N.V. Earnings Call: Financial Strength Amid Challenges - TipRanks

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac NV earnings beat by €0.06, revenue topped estimates - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac: 2025 will be less costly - marketscreener.com

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac Announces Financial Results for the Fourth Quarter and F - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - Yahoo Finance

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience By GuruFocus - Investing.com Canada

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Pa - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

CureVac Reports Strong 2024 Financial Results and Strategic Progress - TipRanks

Apr 10, 2025
pulisher
Apr 10, 2025

CureVac Reports 2024 Financial Results and Strategic Advances - TipRanks

Apr 10, 2025
pulisher
Apr 10, 2025

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - ACCESS Newswire

Apr 10, 2025
pulisher
Apr 10, 2025

CureVac Q4 2024 Earnings Call Transcript - MarketBeat

Apr 10, 2025
pulisher
Apr 09, 2025

Insights Ahead: CureVac's Quarterly Earnings - Benzinga

Apr 09, 2025
pulisher
Apr 09, 2025

CureVac to initiate Phase 1 trial for its lung cancer therapy - MSN

Apr 09, 2025
pulisher
Apr 08, 2025

FDA clears CureVac’s IND application for Phase I lung cancer trial - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

FDA clears Curevac’s IND for CVHNLC - BioWorld MedTech

Apr 08, 2025
pulisher
Apr 08, 2025

EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - sharewise.com

Apr 08, 2025
pulisher
Apr 08, 2025

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 08, 2025

CureVac Financial Results: Key mRNA Biotech Player to Reveal 2024 Performance - Stock Titan

Apr 08, 2025
pulisher
Apr 07, 2025

CureVac’s lung cancer therapy clears FDA hurdle - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

CureVac’s lung cancer therapy clears FDA hurdle By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

CureVac's Early-stage Trial of Lung Cancer Drug Gets US FDA Clearance - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

CureVac to initiate Phase 1 trial for its lung cancer therapy (CVAC:NASDAQ) - Seeking Alpha

Apr 07, 2025
pulisher
Apr 07, 2025

CureVac Receives FDA Clearance to Initiate Phase 1 Trial of Lung Cancer Therapy - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - sharewise.com

Apr 07, 2025
pulisher
Apr 07, 2025

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 05, 2025

CureVac N.V.'s (NASDAQ:CVAC) Profit Outlook - simplywall.st

Apr 05, 2025
pulisher
Apr 02, 2025

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Is CureVac (CVAC) the Best German Stock to Buy According to Hedge Funds? - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

CureVac (NASDAQ:CVAC) Stock Price Down 7.2%What's Next? - MarketBeat

Apr 01, 2025
pulisher
Mar 28, 2025

CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions (NASDAQ:CVAC) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

CureVac (CVAC) Stock Surges After Favorable Patent Ruling - Stocks Telegraph

Mar 28, 2025
pulisher
Mar 28, 2025

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Lululemon, General Motors and Apple fall premarket; CureVac gains By Investing.com - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

Lululemon, General Motors and Apple fall premarket; CureVac gains - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

CureVac, gold miners, Rocket Lab - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

CureVac Patent Validated in BioNTech Dispute, Infringement Hearing Set for July - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

PRTG Soars On Mesothelioma Data, NVNO Awaits FDA Decision, CureVac Jumps On Patent News - RTTNews

Mar 28, 2025
pulisher
Mar 27, 2025

CureVac’s amended patent upheld by European Patent Office By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

European Patent Office declares CureVac mRNA patent valid - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

CureVac up 13% as court upholds validity of patent in BioNTech spat - Seeking Alpha

Mar 27, 2025

Finanzdaten der Curevac N V-Aktie (CVAC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
Kapitalisierung:     |  Volumen (24h):